Inactive Instrument

News Abcam OTC Markets

Stocks

ABCZF

GB00B6774699

Pharmaceuticals

All News

07-23	Abcam Limited Appoints Kaveh Kahen as Director, Effective July 14, 2026	CI
06-18	ABCAM LIMITED Announces Termination of Markus Lusser as Director, Effective June 5, 2026	CI
04-14	Abcam Launches SimpleStep Ignite ELISA	CI
03-10	Abcam Limited Appoints Melanie Hammerschmidt-Broman as Director, Effective March 10, 2026	CI
01-20	Abcam Joins the Innovative Health Initiative LIGAND-AI Project to Advance Artificial Intelligence (AI)-Driven Drug Discovery Through Open Science	CI
01-12	Abcam Limited Announces Termination of Knud Mueller as Director, Effective December 31, 2025	CI
21/10/25	Molecular Instruments and Abcam Announce Broad Compatibility of the HCR HiFi Encoder with Abcam?s Rabmab and Mouse Antibody Portfolio	CI
06/12/23	Danaher Closes Acquisition of Abcam	MT
06/12/23	Danaher completes $5.7 billion acquisition of Abcam	RE
06/12/23	Danaher Completes Acquisition of Abcam	PR
06/12/23	Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Composite Index	CI
06/12/23	Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Biotechnology Index	CI
06/12/23	Abcam plc(NasdaqGS:ABCM) dropped from S&P Global BMI Index	CI
06/12/23	Danaher Corporation completed the acquisition of Abcam plc.	CI
05/12/23	Abcam's Acquisition by Danaher Approved by UK Court	MT
05/12/23	Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales	BU
17/11/23	Abcam Says All Necessary Clearances for Acquisition by Danaher Obtained; Deal Set to be Completed on Dec. 6	MT
17/11/23	Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023	BU
07/11/23	Abcam Shareholders Approve Danaher's Acquisition Offer	MT
07/11/23	Abcam shareholders approve $5.7 billion Danaher deal	RE
07/11/23	Shareholders of Abcam Approve Proposed Acquisition by Danaher	BU
01/11/23	Jonathan Milner Suspends his Vote Against Campaign	CI
01/11/23	Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign	AQ
31/10/23	RBC Trims Price Target on Abcam to $24 From $25, Keeps Sector Perform Rating	MT
23/10/23	Leading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam	BU